Novo Nordisk Sinks on Disappointing Trial Results for Next Gen Weight Loss Drug

Key TakeawaysNovo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it released data from a new weight loss drug trial.The new drug, CagriSema, led patients to lose 22.7% of their body weight on average, below the company's reported goal of 25%, per Bloomberg.The drug combines semaglutide, the active ingredient in Ozempic and Wegovy, with another ingredient meant to reduce hunger and make patients feel full for longer. Novo Nordisk's (NVO) U.S.-listed shares sank over 19% in premarket tradi ...